CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents (Q45185400)

10 December 2017

title

CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents (English)

1 reference

10 December 2017

V K Vyas

1

1 reference

10 December 2017

H G Bhatt

2

1 reference

10 December 2017

P K Patel

3

1 reference

10 December 2017

J Jalu

4

1 reference

10 December 2017

C Chintha

5

1 reference

10 December 2017

N Gupta

6

1 reference

10 December 2017

M Ghate

7

1 reference

10 December 2017

publication date

11 January 2013

1 reference

SAR and QSAR in Environmental Research

10 December 2017

published in

1 reference

10 December 2017

volume

24

1 reference

10 December 2017

issue

7

1 reference

10 December 2017

page(s)

519-551

1 reference

Recent and emerging anti-diabetes targets

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

The sodium/glucose cotransport family SLC5

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

QSAR models of cytochrome P450 enzyme 1A2 inhibitors using CoMFA, CoMSIA and HQSAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Pharmacophore modeling, virtual screening and 3D-QSAR studies of 5-tetrahydroquinolinylidine aminoguanidine derivatives as sodium hydrogen exchanger inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

Development of CoMFA, advance CoMFA and CoMSIA models in pyrroloquinazolines as thrombin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1062936X.2012.751553

10.1080/1062936X.2012.751553

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference